Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
None
Flexible-Dose Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TemPo-3)

The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of "on" time without troublesome dyskinesia in L-Dopa-treated participants with

carbidopa/levodopa
bradykinesia
carbidopa
amantadine
dopa
  • 0 views
  • 12 Sep, 2021
  • 102 locations
None
Epidemiology and Pathophysiology of Parkinsonism in the Caribbeans

The primary aim of this study is to estimate the frequency and to characterize clinically atypical parkinsonism in the French West Indies and Guyana.

  • 0 views
  • 21 Jan, 2021
  • 2 locations
None
Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)

Opicapone (OPC) is a third generation catechol O methyltransferase (COMT) inhibitor (COMTi) developed by BIAL-Portela & C, S.A. It is approved as adjunctive therapy to preparations of L-DOPA

  • 0 views
  • 04 Aug, 2021
  • 1 location
None
Efficacy of RIVAstigmine on Motor Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy

-threatening situations and death occurs 6-9 years after disease onset. Apart from L-dopa which may transiently and inconsistently improve motor symptoms no effective symptomatic, disease-modifying or

dopa
screening procedures
gaze palsy
mini-mental state examination
parkinson's disease
  • 191 views
  • 19 Aug, 2021
  • 1 location
None
First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of Progression

This phase 2 study is a prospective cohort study. Chemotherapy alone will be proposed to adult patients suffering from a "low grade" brainstem glioma subtype showing infiltrative, non-threatening clinico-radiological progression. Patients will receive temozolomide at a monthly standard dose of 150-200 mg/m2/j J1-J5, will be clinically evaluated every month and …

  • 0 views
  • 19 Sep, 2021
None
18F-DOPA II - PET Imaging Optimization

A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: Pediatric patients (less than 18 years

  • 0 views
  • 29 Apr, 2021
  • 1 location
None
[18F]F-DOPA Imaging in Patients With Autonomic Failure

these biomarkers may be related to the neurotransmitter dopamine (DA) and related changes in the substantia nigra (SN) and brainstem. [18F]F-DOPA is a radiolabeled substrate for aromatic amino acid

dementia
atrophy
pure autonomic failure
entacapone
demented
  • 19 views
  • 13 Mar, 2021
  • 1 location
None
Clinical Study on Treatment of L-DOPA-Induced Dyskinesia With Tianqi Pingchan Granule Combined With Amantadine

A randomized, double-blind, placebo-controlled, multi-center clinical trial was conducted to observe the improvement in the level of dyskinesia in patients with Parkinson's disease during the 12-week period of oral treatment with Tianqi Pingchan Granule Combined With Amantadine. To observe the differences of the safety and effectiveness between Tianqi Pingchan Granule …

  • 0 views
  • 27 Jan, 2021
  • 1 location
None
L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults

motor slowing. The central hypothesis of this study is that by enhancing dopamine functioning in the brain and improving cognitive and motor slowing, administration of carbidopa/levodopa (L-DOPA) will

carbidopa/levodopa
psychotic
major depressive disorder
depression
dopamine
  • 0 views
  • 30 Apr, 2021
None
Contribution of Cerebral 18F-DOPA PET-CT Scan in High-grade Recurrent Gliomas

studies have been performed with 18F-DOPA.( 6-fluoro-[18F]-L-dihydroxyphenylalanine) The question therefore relates to the interest of cerebral 18F-DOPA PET-CT to improve the delineation of the volumes to

  • 0 views
  • 12 Aug, 2021
  • 1 location